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Abstract
Background: Urinary Tract Infection (UTI) is one of the most common infectious diseases and people of all age-
groups and geographical locations are affected. The impact of disease is even worst in low-resource developing
countries due to unaware of the UTIs caused by multidrug-resistant (MDR) pathogens and the possibility of transfer
of MDR traits between them. The present study aimed to determine the prevalence of MDR bacterial isolates from
UTI patients, the antibiotic resistance pattern and the conjugational transfer of multidrug resistance phenotypes in
Escherichia coli (E. coli).
Results: Two hundred and nineteen bacterial isolates were recovered from 710 urine samples at Kathmandu
Model hospital during the study period. All samples and isolates were investigated by standard laboratory
procedures. Among the significant bacterial growth (30.8%, 219 isolates), 41.1% isolates were MDR. The most
prevailing organism, E. coli (81.3%, 178 isolates) was 38.2% MDR, whereas second most common organism,
Citrobacter spp. (5%, 11 isolates) was found 72.7% MDR. Extended-spectrum b-lactamase (ESBL) production was
detected in 55.2% of a subset of MDR E. coli isolates. Among the 29 MDR E. coli isolates, plasmids of size ranging
2-51 kb were obtained with different 15 profiles. The most common plasmid of size 32 kb was detected in all of
the plasmid-harbored E. coli strains. The majority of E. coli isolates investigated for the multidrug resistance transfer
were able to transfer plasmid-mediated MDR phenotypes along with ESBL pattern with a frequency ranging from
0.3 × 10
-7 to 1.5 × 10
-7 to an E. coli HB101 recipient strain by conjugation. Most of the donor and recipient strain
showed high levels of minimum inhibitory concentration (MIC) values for commonly-used antibiotics.
Conclusions: The high prevalence of multidrug resistance in bacterial uropathogens was observed. Particularly,
resistance patterns were alarmingly higher for amoxycillin, co-trimoxazole, flouroquinolones and third-generation
cephalosporins, which necessitate the re-evaluation of first and second line therapies for UTI. In addition,
conjugational co-transfer of MDR phenotypes with ESBL-positive phenotypes was observed in MDR E. coli.
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Background
Urinary tract infection is a common bacterial disease,
often contributes to a frequent cause of morbidity in
out-patients as well as hospitalized-patients [1]. Clinical
experience has indicated the presence of numerous
cases of antibiotic resistance to common antibiotics by
uropathogens in both developed and developing coun-
tries [2]. Resistant to newer and more potent
antimicrobials are no exceptions, making the therapeutic
options very limited to certain antimicrobial agents like
carbapenem, colistin and fosfomycin [3]. In many parts
of Nepal, the facilities for urine culture and antimicro-
bial susceptibility testing are still not available, leading
to improper diagnosis and irrational antibiotic treatment
(e.g. self-medication) of UTI [4]. The updated knowl-
edge and situation of the prevailing bacterial uropatho-
gens that are multidrug resistant (MDR) is of prime
importance for the proper use of antimicrobial drugs
and the policy making to combat multidrug resistance
in UTIs [3].
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any medium, provided the original work is properly cited.Invariably, Escherichia coli (E. coli) has been found as a
most common uropathogen in a number of reports
worldwide [5-7]. Antimicrobial therapy of UTI caused by
E. coli is often impaired due to the resistance to com-
monly-used antimicrobial agents [3,5]. Although E. coli
has been reported to be MDR by possessing the antibiotic
resistant genes in its transferable R-plasmid (s) [8], detec-
tion of this feature in UTI isolates from Nepal is largely
unknown. The present study aimed to determine the pre-
valence of MDR bacterial isolates in UTI, the antibiotic
resistance pattern, the plasmid profile of isolated MDR E.
coli, and the transfer of multidrug resistance phenotypes
by conjugation. Our data might be informative to both of
the health professionals and the scientific community,
which may help to make a positive contribution to cur-
rent understanding and knowledge of the situation in
UTI caused by MDR bacterial pathogens.
Methods
Study population and bacterial isolates
This prospective study was carried out at Kathmandu
Model Hospital between 1st May and 30th September
2007. This public hospital is one of big hospitals located
in capital, Kathmandu, where patients across the country
visit regularly. Conduction of this study was approved by
ethics and research committee of Kathmandu Model
Hospital. Written informed consents were obtained from
all cases prior to their inclusion in the study. All sus-
pected patients of UTI during the study period were
interviewed directly with structured questionnaire to col-
lect data about patient’s demographics, type of patient
(hospitalized- or out-patient), symptoms, prior history of
UTI, and underlying diseases. Only those cases with at
least one of the clinical features of UTI (dysuria, fre-
quency, urgency, loin pain or prior history of UTI) were
judged as clinically-suspected patients of UTI and
selected for confirmation of UTI. A total of 710 mid-
stream ‘clean-catched’ urine samples were collected from
the same number of clinically-suspected patients of UTI.
Once the sample was collected, transferred to the labora-
tory immediately and inoculated on blood agar and
McConkey agar using a standard calibrated loop. Isolates
from cases with significant bacteriuria (10
5 colonies/ml)
were identified based upon standard laboratory proce-
dures involving, morphological characteristics, Gram’s
stain, rapid tests (catalase, oxidase, coagulase, bile solubi-
lity), and biochemical tests (IMViC [Indole, methyl red,
Voges-Proskauer and citrate], TSI [triple sugar iron], O/F
[oxidation/fermentation], urease and nitrate reduction)
[9]. Single isolate was selected from each of diagnosed
samples. UTI diagnosis was established on the basis of
pyuria (≥5 leukocytes per high-power field on micro-
scopic examination of the urine), clinical feature (s) (as
mentioned above) and significant bacteriuria.
Antimicrobial susceptibility testing and MIC testing
Antimicrobial susceptibility patterns were determined
according to the Clinical and Laboratory Standards
Institute (CLSI)-recommended modified Kirby-Bauer
disc diffusion method on Mueller-Hinton agar with
commercial antibiotic discs (Oxoid Ltd, UK) [10]. Sus-
ceptibility to eight antimicrobial agents (amoxycillin,
cefotaxime, cefixime, ciprofloxacin, cotrimoxazole, nitro-
furantoin, norfloxacin and ofloxacin; used as primary)
was determined for 209 g- negative bacterial isolates. Of
these, 56 isolates were tested by additional antibiotic
discs (amikacin, chloramphenicol, ceftazidime, ceftriax-
one and gentamycin; used as secondary). Susceptibility
to seven antimicrobial agents (amoxycillin, cephalexin,
ciprofloxacin, cotrimoxazole, cloxacillin, erythromycin
and norfloxacin) was determined for all 10 g- positive
isolates. Four of these isolates were also tested by an
additional antibiotic disc (vancomycin). Antibiotic con-
centrations in the diffusion discs used for antimicrobial
susceptibility testing are: amikacin (30 μg), amoxycillin
(10 μg), cefixime (5 μg), cefotaxime (30 μg), ceftazidime
(30 μg), ceftriaxone (30 μg), cephalexin (30 μg), chlor-
amphenicol (30 μg), ciprofloxacin (5 μg), cloxacillin (5
μg), co-trimoxazole (1.25/23.75 μg), erythromycin (15
μg), gentamycin (10 μg), nitrofurantoin (300 μg), nor-
floxacin (10 μg), ofloxacin (5 μg) and vancomycin (30
μg). Escherichia coli (ATCC 25922) and Staphylococcus
aureus (ATCC 25923) were used as controls for Gram-
negative and Gram positive bacteria, respectively.
Those organisms which showed resistance to at least
three or more antibiotics of different structural classes
were considered MDR as described elsewhere [11,12].
MDR E. coli isolates were preservedi nt y r p t i cs o yb r o t h
containing 20% glycerol at -70°C until further investigation.
Minimum inhibitory concentration (MIC) for donors
and transconjugants was determined by two fold broth
macrodilution method as recommended by CLSI [13].
The inocula of 4 × 10
5 colony forming unit (CFU) were
prepared from suitably diluted overnight broth culture at
37°C. Positive growth controls were kept for each isolates
and E. coli 25922 of known MIC was also included in each
test as control for antibiotic potency. MIC was defined as
the minimum concentration of antimicrobial agent that
prevented the visible growth of bacteria. The range of anti-
biotic concentrations employed in MIC test is: ampicillin
(1-512 μg/ml), ciprofloxacin (0.016-256 μg/ml), cefixime
(1-512 μg/ml), chloramphenicol (1-512 μg/ml), norfloxacin
(0.016-256 μg/ml), co-trimoxazole (1-512 μg/ml) and gen-
tamycin (0.5-64 μg/ml). The antibiotic powders were pro-
vided by National Drug Laboratory, Kathmandu, Nepal
Determination of ESBL production
The ESBL-producing phenotypes from the 29 MDR
E. coli isolates were determined by Kirby-Bauer disc
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Amoxy-clavulanic acid (20/10 μg) disc (Oxoid Ltd, UK)
was placed in the center of ceftazidime (30 μg) and
cefotaxime (30 μg) discs with 25-30 mm apart. After
overnight incubation at 37°C in air, confirmation of
ESBL-producing organism was assessed when the zone
of inhibition around ceftazidime and cefotaxime was
expanded by at least 5 mm by the presence of clavulanic
acid [14]. E. coli ATCC 25922 and Klebsiella pneumo-
niae ATCC 700603 were used as negative and positive
controls for ESBL production, respectively.
Plasmid profiles and conjugation
Plasmid DNA from MDR E. coli was extracted from the
overnight culture (mid log phase) grown in Lauria-Ber-
tani (LB) broth supplemented with antibiotic (100 μg/ml
of ampicillin). The plasmid DNA was extracted and pur-
ified using a QIAprep spin miniprep kit (Qiagen, Ger-
many) according to the manufacturer’s instruction.
Considering that the isolation of large plasmid may be
affected using miniprep, isolation was carried out addi-
tional two times for those large plasmid ( > 20 kb) to be
ensured about the proper plasmid size and number in
the isolates. The plasmid DNA was analyzed through
0.5% horizontal agarose gel electrophoresis. Electrophor-
esis was run at 0.6 Vcm
-2 for 4 h in TAE buffer (40 mM
Tris-acetate, 1 mM EDTA). Reference supercoiled plas-
mid DNA marker (New England Biolab, England) and
plasmid from E. coli V517 were used for the estimation
of plasmid sizes.
The MDR E. coli strains showing sensitivity to strepto-
mycin were selected for conjugation study, serving as
donors. The plasmid-free, streptomycin-resistant strain
of E. coli (E. coli HB 101), showing sensitivity to all anti-
biotics under study, was used as a recipient. Conjugation
was carried out as similarly described elsewhere [8].
Briefly, all donor E. coli strains and recipient E. coli
strain were grown with antibiotic supplement till the O.
D. of each type reaches 0.85 at A600 (approximately 10
8
cells/ml). Each of 0.2 ml donor and recipient culture
broth were mixed together in 2.5 ml warm LB broth
and incubated at 37°C without shaking. After 24 h. of
incubation, bacteria were then plated onto selective LB
agar supplemented with streptomycin (100 μg/ml) and
at least one of the following antibiotics: ampicillin (30
μg/ml), ciprofloxacin (0.045 μg/ml), cefixime (2 μg/ml),
chloramphenicol (20 μg/ml), norfloxacin (0.3 μg/ml), tri-
methoprim (200 μg/ml), cefotaxime (2 μg/ml) and gen-
tamycin (10 μg/ml). It should be noted that the
indicated concentrations of above antibiotics inhibited
the growth of recipient strain E. coli HB101 only, but
not donors. The transconjugants were identified based
upon the visible growth on these counter-antibiotic con-
taining medium and subjected for plasmid profiling. To
ensure the transconjugants selection only by conjuga-
tion, not by mutation that can alter the streptomycin
susceptibility in the donor strains, controls (for donor
and recipient strain) were run in each conjugation
experiment parallely, involving similar procedure of con-
jugation, but without adding recipient culture broth (for
donor control) and donor culture broth (for recipient
control). Successful conjugation was ascertained by find-
ing no growth from controls, while visible growth from
the conjugation mixture bacteria, in LB agar supplemen-
ted with streptomycin and at least one of aforemen-
tioned antibiotics. The antibiogram of the donors and
transconjugants were studied by disc diffusion method
and MIC testing as described above.
Statistical analysis
The data was analyzed by using Minitab version 15
(Minitab Inc., USA). Statistical tests of significance were
performed using the Kruskall-Wallis test. A p value of ≤
0.05 was considered significant.
Results
Bacterial uropathogens
Two-hundred and nineteen bacterial pathogens (30.8%)
were isolated from the 710 clinically-suspected cases of
UTIs. High incidences of UTI cases were observed,
among female patients (33.5%, 173/516) than male
patients (23.7%, 46/194) (p < 0.05), and in hospitalized-
patients (51.3%, 20/39) than out-patients (29.7%, 199/
671) (p < 0.05). Out of the 219 isolates, Gram-negative
bacilli accounted for 95.4% while Gram-positive cocci
accounted for the remaining 4.6% of the total isolates.
The most common urinary pathogen isolated was E. coIi
(81.3%), followed by Citrobacter spp. (5%) and coagu-
lase-negative staphylococci (CoNS) [2.7%; S. epidermidis
(1.8%) and S. saprophyticus (0.9%)] (Table 1). The per-
cent resistance to antibiotics shown by the Gram-nega-
tive pathogens are shown in Table 2. E. coli showed the
high resistance rate against most of the primary drugs
tested: amoxycillin (55.6%), co-trimoxazole (54.4%), nor-
floxacin (36.5%), ciprofloxacin (35.9%) and cefixime
(30.3%). Comparatively, it showed low resistance rate
against a primary drug, nitrofurantoin (7.9%). Out of the
13 antibiotics tested for E. coli isolates, the least resis-
tance was observed to amikacin (6.2%) (Table 2).
The most predominant Gram-positive isolates, CoNS,
showed a least resistance (16.7% in each) against the pri-
mary antibiotics (amoxycillin, ciprofloxacin, erythromy-
cin and norfloxacin).
Multidrug resistance in bacterial uropathogens
Out of the 219 isolates, 41.1% were MDR according to
the mentioned criteria. High incidence of UTIs caused
by MDR pathogens was observed, among male patients
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< 0.05), also in hospitalized-patients (85%, 17/20) than
out-patients (36.7%, 73/199) (p < 0.05). Although multi-
drug resistance was shown 100% by Enterococcus faeca-
lis, Salmonella typhi, Staphylococcus aureus and
Pseudomonas aeruginosa, these were low in number and
considered insignificant. Out of the 178 E. coli isolates,
38.2% were confirmed to be MDR (Table 1). E. coli
(75.5%, 68/90) and Citrobacter spp. (8.9%, 8/90) shared
the major part of MDR isolates (Table 1). The MDR E.
coli isolates demonstrated the extended resistance pat-
tern to different classes of antibiotics, such as 7.3% iso-
lates showed resistance to 5-6 classes (Table 3).
Majority of MDR E. coli isolates showed high resis-
tance to different classes of antibiotics used: co-trimoxa-
zole (86.8%), penicillin (amoxycillin, 94.1%), quinolone
(ciprofloxacin and ofloxacin [92.6% in each]), cephalos-
porin (cefotaxime [79.4%] and cefixime [77.9%]) and
nitrofurantoin (17.6%). Similarly, these MDR isolates
were also shown high antibiotic resistance among the
secondary antibiotics evaluated e.g. cephalosporin (cefta-
zidime and ceftriaxone [100% in each]), aminoglycosides
(gentamycin [72.9%] and amikacin [6.2%]) and chloram-
phenicol (27.1%). The most common three types of mul-
tidrug resistance pattern by these MDR E. coli isolates,
in respective order, include resistance to: amoxycilin,
ciprofloxacin, cephotaxime, cefixime, cotrimoxazole,
ofloxacin, norfloxacin, ceftazidime, gentamycin, ceftriax-
one; amoxycilin, ciprofloxacin, cephotaxime, cefixime,
cotrimoxazole, ofloxacin, norfloxacin, ceftazidime and
amoxycilin, ciprofloxacin, cefixime, cotrimoxazole,
ofloxacin, norfloxacin, ceftazidime, chloramphenicol,
gentamycin, ceftriaxone.
ESBL production, plasmid profiling and multidrug
resistance transfer
Out of the 68 MDR E. coli isolates, 29 isolates repre-
senting the most common MDR patterns were further
analyzed for ESBL production and plasmid profiling.
ESBL production was detected in 16 (55.2%) isolates. All
MDR E. coli isolates that were analyzed for plasmid pro-
files harbored at least single plasmid. Altogether 15 dif-
ferent types of plasmid profiles of size ranging from 2 to
51 kb were detected. Of which, 12 isolates showed single
plasmid, 3 showed double plasmids, whereas 6, 6, 1 and
1 isolates showed 3, 4, 5, and 7 plasmids, respectively.
The most common plasmid of size 32.5 kb was detected
in the majority of the plasmid-harbored MDR E. coli
strains. Out of the 29 plasmid-harbored MDR E. coli
isolates, 10 isolates were screened and selected for con-
jugation study. Each of the isolates containing either sin-
gle or multiple plasmids can transfer single or multiple
plasmids to the recipient strain by conjugation. The
highest transfer of plasmid of size 51 kb was detected by
conjugation experiment. The MDR pattern (amoxycillin-
, ciprofloxacin-, cefixime-, cotrimoxazole-, ofloxacin-,
and norfloxacin-resistance) was found most likely to be
transferred to recipient strain by conjugation with high-
est conjugation frequency of 1.5 × 10
-7(Table 4).
Majority of donor strains (85.7%, 6 isolates) can trans-
fer the ESBL production phenotype to the recipient
strain by conjugation (Table 4). Most of the donors and
Table 1 Distribution of MDR bacterial uropathogens
Organism In hospitalized-patient In out-patient Total
No of isolates
(%)
No of MDR isolates
(%)
No of isolates
(%)
No of MDR isolates
(%)
No of isolates (% of
total)
No of MDR isolates
(%)
Acinetobacter spp. 1 1 (100) 1 0(0) 2 (0.9) 1 (50)
Citrobacter spp. 5 5 (100) 6 3 (50) 11 (5) 8 (72.7)
Enterobacter spp. 0 0 (0) 4 1 (25) 4 (1.8) 1 (25)
Escherichia coli 11 8 (72.7) 167 60 (35.9) 178 (81.3) 68 (38.2)
Klebsiella oxytoca 0 0 (0) 2 1 (50) 2 (0.9) 1 (50)
K. pneumoniae 0 0 (0) 4 1 (25) 4 (1.8) 1 (25)
Morganella morganii 0 0 (0) 2 0 (0) 2 (0.9) 0 (0)
Proteus mirabilis 0 0 (0) 3 0 (0) 3 (1.4) 0 (0)
Pseudomonas
aeruginosa
0 0 (0) 2 2 (100) 2 (0.9) 2 (100)
Salmonella typhi 1 1(100) 0 0(0) 1 (0.5) 1 (100)
Staphylococcus
aureus
0 0(0) 1 1 (100) 1 (0.5) 1 (100)
CoNS* 1 1 (100) 5 2 (40) 6 (2.7) 3 (50)
Enterococcus faecalis 1 1(100) 2 2 (100) 3 (1.4) 3 (100)
Total 20 17 (85) 199 73 (36.7) 219 (100) 90 (41.1)
*CoNS = coagulase-negative staphylococci
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Antibiotic Escherichia
coli
Klebsiella
spp.
Proteus
mirabilis
Pseudomonas
aeruginosa
Enterobacter
spp.
Citrobacter
spp.
Acinetobacter
spp.
Salmonella
typhi
Morganella
morganii
No of resistant
isolates/total
isolates (%
resistance)
Amoxycillin(Am) 99/178(55.6) 6/6(100) 1/3(33.3) NT NT 8/11(72.7) 1/2(50) 1/1(100) NT 116/201 (57.7)
Cefotaxime(Ce) 54/178(30.3) 2/6(33.3) 0/3(0) 1/2(50) 1/4(25) 7/11(63.6) 1/2(50) 0/1(0) 0/2(0) 66/209 (31.6)
Ciprofloxacin(Cf) 64/178(35.9) 1/6(16.7) 0/3(0) 1/2(50) 0/4(0) 6/11(54.5) 0/2(0) 1/1(100) 0/2(0) 73/209 (34.9)
Cefixime(Cfx) 54/178(30.3) 2/6(33.3) 0/3(0) 2/2(100) 1/4(25) 8/11(72.7) 1/2(50) 0/1(0) 0/2(0) 68/209 (32.5)
Cotrimoxazole(Co) 97/178(54.4) 2/6(33.3) 1/3(33.4) 2/2(100) 1/4(25) 8/11(72.7) 1/2(50) 0/1(0) 0/2(0) 112/209 (53.6)
Nitrofurantoin(Nf) 14/178(7.9) 4/6(66.6) NT NT 1/4(25) 5/11(45.4) 2/2(100) 1/1(100) NT 27/202 (13.4)
Norfloxacin(Nx) 65/178(36.5) 1/6(16.7) 0/3(0) 2/2(100) 0/4(0) 6/11(54.5) 1/2(50) 1/1(100) 0/2(0) 76/209 (36.4)
Ofloxacin(Of) 63/178(35.4) 1/6(16.7) 0/3(0) 2/2(100) 0/4(0) 4/11(36.4) 1/2(50) 1/1(100) 0/2(0) 72/209 (34.4)
Amikacin(Ak) 3/48(6.2) 0/1(0) NT 0/2(0) NT 4/5(80) 0/2(0) 0/1(0) NT 7/59 (11.9)
Chloramphenicol(C) 13/48(27.1) 1/1(100) NT 2/2(100) NT 5/5(100) 0/2(0) 0/1(0) NT 21/59 (35.6)
Ceftazidime(Ca) 48/48(100) 1/1(100) NT 2/2(100) NT 5/5(100) 1/2(50) 0/1(0) NT 57/59 (96.6)
Ceftriaxone(Ci) 48/48(100) 0/1(0) NT 2/2(100) NT 3/5(60) 1/2(50) 0/1(0) NT 54/59 (91.5)
Gentamycin(G) 35/48(72.9) 1/1(100) NT 2/2(100) NT 5/5(100) 0/2(0) 0/1(0) NT 43/59 (72.9)
The numbers within non-parentheses indicate the number of resistant isolates by total number isolates and the numbers within parentheses indicate the percent resistance
NT: not tested
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9transconjugants showed high MIC values for the anti-
biotics tested, upto ≥512 μg/ml (ampicillin, chloramphe-
nicol, cefixime, and trimethoprim) and ≥64 μg/ml
(ciprofloxacin, norfloxacin and gentamycin) (Table 4).
Discussion
The present study provides the information about the
distribution and the antibiotic resistance pattern of bac-
terial pathogens isolated from the UTI patients from
Nepal. In addition, to our knowledge, this is the first
report to indicate a possible plasmid-mediated transfer
of multidrug resistance among MDR E. coli isolates
from UTIs in Nepal. Our study showed that Enterobac-
teriaceae are predominant causative organisms to cause
UTI, followed by Gram-positive cocci, a finding consis-
tent with reports published elsewhere [15,16]. Among
the Gram-negative bacteria, highest percents of resis-
tance towards first-line antibiotics were found for amox-
ycillin (57.7%), co-trimoxazole (53.6%), and norfloxacin
(36.4%). However, overall amikacin and nitrofurantoin
showed a least resistance, 11.9% and 13.4%, respectively.
Among Gram-positive pathogens, CoNS were found
most predominant and were resistant to cephalexin
(33.4%), cloxacillin (33.4%) and co-trimoxazole (33.4%)
in the first-line of antibiotics. Although most of the S.
aureus and enterococci species were found resistant to
b-lactam antibiotics, fortunately resistance towards van-
comycin was not observed. These results are basically in
agreement with other studies [15,17].
Our report, similar to previous reports, shows that E.
coli is the predominant causative agent of UTIs with high
rate of antibiotic resistance [6,7,16,18]. Out of the 178 E.
coli isolates, 55.6% showed resistance to amoxycillin,
54.4% to co-trimoxazole, 36.5% to norfloxacin and 35.9%
to ciprofloxacin. Amoxycillin and co-trimoxazole resis-
tance rates in our report were higher in comparison to
other reports, hence empirical therapy with these antibio-
tics seems inadequate and should be avoided [6,18].
Among the antibiotics evaluated secondarily, amikacin
was found most effective to all of the E. coli isolates
tested. Our results show a substantial increase in the
resistance to quinolones by E. coli isolates, an observa-
tion also reported by others [12,16,19]. Since nitrofuran-
toin has shown low overall E. coli and other isolates
resistance rate in both hospitalized- and out-patients, it
can be considered as the first-line therapy, a finding
similar to other studies [12,20,21]. Similarly, overall
resistance to aminoglycosides was comparatively low.
This is consistent with previous studies of antimicrobial
susceptibility in UTI infections. For examples, Aypak et
al. showed the 6.1% resistance by E. coli [18], and Bean
et al. showed the 6.7% resistance [20].
In our report, we found a high incidence of MDR
UTIs in both hospitalized-patients (85%) and out-
patients (36.7%), however the difference between two
groups is significant. It gives the impression of extensive
dissemination of MDR uropathogens in both community
and hospital environment. The contributing factors for
the appearance of such high bacterial antibiotic resis-
tance in UTIs from both groups of patients may be
numerous. One of them might be the injudicious use of
antimicrobial agents, for example, self-medication,
which is a common practice of antibiotic misuses in
Nepal. In our study, we observed high incidence of UTI
caused by MDR pathogens in male patients than female
patients. It might be due to the reason that the inci-
dence of UTIs among male patients is often associated
with old age and/or using of mechanical devices, both of
these factors have been found to contribute the multi-
drug resistance phenotype [22]. We observed high mul-
tidrug resistance rate in Enterobacteriaceae isolates as
7.3% E. coli and 18.2% Citrobacter spp. showed antibio-
tic resistance to > 5-6 classes (Table 3). In our report,
the most prevalent MDR pattern shown by E. coli
includes resistance to: amoxycillin, ciprofloxacin, cepho-
taxime, cefixime, co-trimoxazole, ofloxacin, norfloxacin,
ceftazidime, gentamycin and ceftriaxone. Most of the
MDR E. coli isolates showed high resistance rate to dif-
ferent classes of antibiotics. Our these findings are com-
patible with the reports from different parts of the
world, including Nepal [6,16,18,21,23]. Our findings sug-
gest that the antibiotic treatment options for UTIs
caused by E. coli have severely impaired due to the
resistance to commonly-used antibiotics, which might
lead to the situation to rely only on certain antibiotics
like fosfomycin, colistin and carbapenem.
Table 3 Distribution of MDR isolates resistant to
indicated class range of antibiotics
Organism 3-4
classes
5-6
classes
≥7
classes
Total
n% n% n % n %
Acinetobacter spp.(n = 2) 1 50 0 0 0 0 1 50
Citrobacter spp. (n = 11) 6 54.5 1 9.1 1 9.1 8 72.7
CoNS* (n = 6) 1 16.7 2 33.3 0 0 3 50
E. coli (n = 178) 54 30.3 13 7.3 1 0.6 68 38.2
Enterobacter spp.(n = 4) 1 25 0 0 0 0 1 25
K. oxytoca (n = 2) 1 50 0 0 0 0 1 50
K. pneumoniae (n = 4) 1 25 0 0 0 0 1 25
M. morganii (n = 2) 0 0 0 0 0 0 0 0
P. mirabilis (n = 3) 0 0 0 0 0 0 0 0
P. aeruginosa (n = 2) 0 0 2 100 0 0 2 100
S. typhi (n = 1) 1 100 0 0 1 100
S. aureus (n = 1) 0 0 0 0 1 100 1 100
E. faecalis (n = 3) 2 66.7 1 33.3 0 0 3 100
Total (n = 219) 68 31 19 8.7 3 1.4 90 41.1
*CoNS = coagulase-negative staphylococci
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phenotypes (55.2%) in a subset of MDR E. coli isolates.
ESBL-producing isolates are often found to show co-
resistance to many classes of antibiotics [24]. This might
be a reason of high multidrug resistance phenotypes
among E.coli isolates in our study. Especially, the
increased resistance observed to fluoroquinolone, ami-
nopenicillin and cephalosporins are striking, because
these antibiotics are first choice to treat UTI in Nepal.
Our data, indicating the enormous bias to bulk MDR E.
coli isolation, hint the possibility of emergence and
spread of dominant UTI- causing MDR E. coli strain by
mutation, in the locality. Although such possibility is
contradictory to other reports, where non-E. coli isolates
also share the major part of MDR UTI isolates [6,21].
The previous reports on uropathogens and their antimi-
crobial susceptibility pattern from different regions of
Nepal also gives the impression of existence of such
situation in Nepal [25-27]. In support, a study in Den-
mark indicated that the mutational events, not clonal
Table 4 Conjugational transfer of multidrug resistance phenotypes in E. coli
Donor Transconjugant
cMIC (μg/ml) of antibiotics towards donors and
transconjugants
aConjugation
frequency
Resistance
pattern
Plasmid
(kb)
bESBL
activity
Resistance
pattern
Plasmid
(kb)
bESBL
activity
Am C Cf Cfx G Nx Co
Am, Cf, Ce, Cfx,
Co, Of, Nx,
Ca, C
32.5 - Am, Cf, Cfx,
Co, Of, Nx
32.5 - D > 512 > 256 > 512 128 512 0.3 × 10
-7
T > 512 64 > 512 64 512
Am, Cf, Ce, Cfx,
Co, Of, Nx,
Ca, C, G, Ci
32.5 + Am, Cf, Cfx,
Co, Of, Nx
32.5 + D > 512 > 256 > 512 > 256 > 512 0.6 × 10
-7
T > 512 64 512 64 > 512
Am, Cf, Co, Nx,
Na, Of, Ca, Ci
32.5 + Am, Cf, Cfx,
Co, Of, Nx
32.5 + D > 512 > 256 > 512 > 256 > 512 1.5 × 10
-7
T > 512 128 > 512 64 512
Am, Cf, Ce, Cfx,
Co, Of, Nx,
Ca, G, Ci
32.5 - Am, Cf, Cfx,
Co, Of, Nx
32.5 - D 512 > 256 > 512 > 256 > 512 0.6 × 10
-7
T 512 64 512 64 512
Am, Cf, Ce, Cfx,
Co, Of, Nx,
Ca, C, G, Ci
32.5, 4.7 + Am, Cf, Cfx,
Co, Of, Nx,
C, G
32.5 + D > 512 512 > 256 > 512 > 64 > 256 > 512 1.2 × 10
-7
T > 512 512 128 512 > 64 128 > 512
Am, Cf, Ce, Cfx,
Co, Of, Nx,
Ca, G, Ci
51 + Am, Cf, Cfx,
Co, Of, Nx
51 - D 512 > 128 512 128 512 0.5 × 10
-7
T 256 32 256 32 512
Am, Cf, Ce, Cfx,
Co, Of, Nx,
Ak, Ca, G, Ci
38 + Am, Cf, Cfx,
Co, Of, Nx
38 + D > 512 > 256 > 512 > 256 > 512 0.8 × 10
-7
T > 512 64 > 512 64 > 512
Am, Cf, Co, Nx,
Ca, Ci
38 - Am, Cf, Cfx,
Co, Of, Nx
38 - D 512 128 > 512 128 512 0.5 × 10
-7
T 256 64 256 64 512
Am, Cf, Ce, Cfx,
Co, Of, Nx,
C, Ca, G, Ci
32.5, 6.5 + Am, Cf, Cfx,
Co, Of, Nx
32.5, 6.5 + D 512 128 > 512 128 > 512 0.3 × 10
-7
T 512 64 > 512 64 > 512
Am, Cf, Ce, Cfx,
Co, Of, Nx,
Ca, Ci
32.5 + Am, Cf, Cfx,
Co, Of, Nx
32.5 + D > 512 128 > 512 128 > 512 1.2 × 10
-7
T > 512 64 > 512 64 512
aConjugation frequency is the number of transconjugants per donor cell
bESBL = extended-spectrum b-lactamase
cMIC = minimum inhibitory concentration of antibiotic at which visible growth of isolates were inhibited
Am-amoxycillin, Ce-cefotaxime, Cfx-cefixime, Cf-ciprofloxacin, Co-cotrimoxazole, Nf-nitrofurantoin, Nx-norfloxacin, Of-ofloxacin, Ak-amikacin, C-chloramphenicol,
Ca-ceftazidime, Ci-ceftriaxone, G-gentamycin, D-donor, T-transconjugant
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of UTI-causing MDR E. coli, due to the increased use of
fluoroquinolone [28]. Further molecular study including
large number of isolates from different geographical
regions of Nepal are needed to confirm the possibility of
selection and spread of dominant MDR E. coli strain in
the locality.
We found a wide range of plasmids of size 2 kb to 51
k b ,a ss i m i l a rt oo t h e r s ,i ns e l e c t e dE. coli isolates. [29].
However, we did not find very large plasmids, as evi-
denced by other [30]. In our conjugation study, most of
the transconjugants showed the MDR phenotypes and
ESBL-producing phenotypes similar to donors. In our
report, transconjugants having large mobilizable plas-
mids of size 32.5 kb, 38 kb and 51 kb were found resis-
tant to at least amoxycillin, ciprofloxacin, cotrimoxazole,
ofloxacin and norfloxacin (Table 4). Our these findings,
similar to others, suggest the possibility of existence of
plasmid-mediated broad-spectum multidrug resistance
in uropathogens [31-34]. Additionally, we also observed
the transfer of comparably small plasmids along with
large plasmids by conjugation. The conjugation fre-
quency of the MDR E. coli strains ranges from 0.3 × 10
-
7 to 1.5 × 10
-7. Similar to this, the conjugation frequency
of 10
-7 was also found with transfer of five antibiotic
resistance patterns in E. coli AB 1157 recipient strain
[8]. Similar to donors, the MIC of the tested antibiotics
towards the transconjugants was also high, except fluor-
oquinolones. The high MIC values shown by donors as
well as recipient E. coli strain suggest the existence of
high levels of transferable multidrug resistance in uro-
pathogens. However, the transfer of high level fluoroqui-
nolone resistance was not observed substantially by
conjugation. This finding is consistent with other
reports [35,36]. Such high levels of multidrug resistance
among uropathogens have also been reported in other
country [28,37]. Altogether, our findings suggest that
there might be the transfer of antibiotic resistance genes
by conjugation often en bloc in self-transferable or
mobilizable plasmids, which might be responsible for
the appearance of high multi drug resistance among
bacterial uropathogens. Further studies involving mole-
cular typing of antibiotic-resistant genes in plasmids are
required to determine such possibility.
Conclusion
We observed the high prevalence of multidrug resistance
among bacterial uropathogens. Particularly, rate of resis-
tance to amoxycillin, co-trimoxazole, flouroquinolones
and third-generation cephalosporins were higher and
these antibiotics should be avoided for empirical-based
therapy of UTIs. In such cases, empirical treatment with
nitrofurantoin and amikacin might provide much better
antibiotic coverage. In addition, we found that the MDR
E. coli isolates causing UTIs are capable of transferring
MDR phenotypes with concomitant transfer of ESBL
phenotypes to E. coli HB101 strain via conjugation. Alto-
gether, our findings indicate the urgency to re-evaluate
the first and second line of drugs for the antimicrobial
therapy of UTIs. Regular national wise surveillance of
multidrug resistance seems necessary step to combat the
UTIs caused by MDR bacterial pathogens.
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